Severe acute pancreatitis following Afatinib treatment in a lung cancer patient
Advances in Digestive Medicine · 2024-12 · 11 (4) · 230-231
DOI: 10.1002/aid2.13404 ↗At a glance
Journal article in Advances in Digestive Medicine, published online on 2024-05-02. Written by Chia‐Hsuan Tsai and 1 co-authors. Cited 2 times so far (Crossref); 5 references.
Abstract (original language)
Molecular targeted therapy associated pancreatitis was usually reported mild, focal, and managed conservatively with discontinuation.1 Afatinib is an epidermal growth factor receptor tyrosine kinase inhibitor that is commonly used as the first-line treatment for patients with metastatic non-small-cell lung cancer.2 The US food and drug agency had launched the post marketing warning for the adverse reactions of pancreatitis associated with Afatinib.3 However, there are fewer cases reported currently. Acute pancreatitis is a condition commonly caused by gall bladder stones, chronic alcohol abuse, hypertriglyceridemia, post-endoscopic retrograde cholangiopancreatography, genetic predisposition, or certain medications (such as steroids, sulfonamides, and thiazides).4 Autoimmune pancreatitis is characterized by high levels of immunoglobulin G4 antibody.5 However, some idiopathic pancreatitis could challenge the diagnosis and treatment. We are presenting a 59-year-old female patient with a medical history of lung adenocarcinoma, left nasopharyngeal carcinoma, insomnia, and depression. She had been receiving Afatinib treatment for almost 10 months. The daily dosage of Afatinib remained at 30 mg and was not altered when diarrhea, skin rash, and recurrent gritty pain in the right eye were observed. Following the initiation of Afatinib, the patient underwent blood tests for lipase levels (
Cite
APA
Tsai, C., & Wang, C. (2024). Severe acute pancreatitis following Afatinib treatment in a lung cancer patient. Advances in Digestive Medicine, 11(4), 230-231. https://doi.org/10.1002/aid2.13404
Vancouver
Tsai C, Wang C. Severe acute pancreatitis following Afatinib treatment in a lung cancer patient. Advances in Digestive Medicine. 2024;11(4):230-231. doi:10.1002/aid2.13404
BibTeX
@article{Tsai2024,
author = {Tsai, Chia‐Hsuan and Wang, Chih‐Wen},
title = {Severe acute pancreatitis following Afatinib treatment in a lung cancer patient},
journal = {Advances in Digestive Medicine},
year = {2024},
volume = {11},
number = {4},
pages = {230--231},
doi = {10.1002/aid2.13404}
}
EUVIMED